Serum Amdl Dr-70 Levels: A New Concept in the Diagnosis and Follow-Up of Colorectal Carcinoma

References

• Tang JQ , FanQ, WuWHet al. Extrahepatic synthesis of coagulation factor VII by colorectal cancer cells promotes tumor invasion and metastasis. Chin. Med. J. (Engl.)123(24), 3559–3565 (2010).
   PubMed Web of Science ®Google Scholar
• Gerner C , SteinkellnerW, HolzmannKet al. Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis. Thromb. Haemost.85(3), 494–501 (2001).
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk J , PonczekMB. The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression. Contemp. Oncol. (Pozn).17(2), 113–119 (2013).
   PubMed Web of Science ®Google Scholar
• Oya M , AkiyamaY, YanagidaT, AkaoS, IshikawaH. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg. Today28(4), 373–378 (1998).
   PubMed Web of Science ®Google Scholar
• Simpson-Haidaris PJ , RybarczykB. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann. NY Acad. Sci.936, 406–425 (2001).
   PubMed Web of Science ®Google Scholar
• Lech G , SlotwinskiR, SlodkowskiM, KrasnodebskiIW. Colorectal cancer tumour markers and biomarkers: recent therapeutic advances. World J. Gastroenterol.22(5), 1745–1755 (2016).
   PubMed Web of Science ®Google Scholar
• Cuyle PJ , PrenenH. Current and future biomarkers in the treatment of colorectal cancer. Acta Clin. Belg.72(2), 103–115 (2017).
   PubMed Web of Science ®Google Scholar
• Nagy Z , HorvathO, KadasJet al. D-dimer as a potential prognostic marker. Pathol. Oncol. Res.18(3), 669–674 (2012).
   PubMed Web of Science ®Google Scholar
• Cohen JF , KorevaarDA, AltmanDGet al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open6(11), e012799 (2016).
   PubMed Web of Science ®Google Scholar
• Locker GY , HamiltonS, HarrisJet al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol.24(33), 5313–5327 (2006).
   PubMed Web of Science ®Google Scholar
• Charalabopoulos K , KarakostaA, BablekosGet al. CEA levels in serum and BAL in patients suffering from lung cancer: correlation with individuals presenting benign lung lesions and healthy volunteers. Med. Oncol.24(2), 219–225 (2007).
   PubMed Web of Science ®Google Scholar
• Wu D , ZhouX, YangGet al. Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection. J. Immunoassay19(1), 63–72 (1998).
   PubMedGoogle Scholar
• Lin SZ , ChenCC, LeeKCet al. DR-70 immunoassay for the surveillance of hepatocellular carcinoma. J. Gastroenterol. Hepatol.27(3), 547–552 (2012).
   PubMed Web of Science ®Google Scholar
• Kerber A , TrojanJ, HerrlingerK, ZgourasD, CasparyWF, BradenB. The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study. Aliment. Pharmacol. Ther.20(9), 983–987 (2004).
   PubMed Web of Science ®Google Scholar
• Shimwell NJ , WeiW, WilsonSet al. Assessment of novel combinations of biomarkers for the detection of colorectal cancer. Cancer Biomark.7(3), 123–132 (2010).
   PubMed Web of Science ®Google Scholar
• Small-Howard AL , HarrisH. Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients. J. Immunoassay Immunochem.31(2), 131–147 (2010).
   PubMed Web of Science ®Google Scholar
• Yesil A , BabacanAbanonu G, ColakY, PakerN, GonenC. Prognostic significance of DR-70 levels in dysplastic colorectal polyps. Gastroenterol. Res. Pract.2013, 275392 (2013).
   PubMed Web of Science ®Google Scholar
• Secco GB , FardelliR, GianquintoDet al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur. J. Surg. Oncol.28(4), 418–423 (2002).
   PubMedGoogle Scholar
• Henry JT , JohnsonB. Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer. Chin. Clin. Oncol.8(5), 49 (2019).
   PubMed Web of Science ®Google Scholar
• Taieb J , JungA, Sartore-BianchiAet al. The evolving biomarker landscape for treatment selection in metastatic colorectal cancer. Drugs79(13), 1375–1394 (2019).
   PubMed Web of Science ®Google Scholar
• Molloy MP , EngelA. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia. Expert Rev. Gastroenterol. Hepatol.12(12), 1179–1181 (2018).
   PubMed Web of Science ®Google Scholar
• Turano M , DelrioP, RegaDet al. Promising colorectal cancer biomarkers for precision prevention and therapy. Cancers (Basel)11(12), pii:E1932 (2019).
   PubMed Web of Science ®Google Scholar
• Schirripa M , CohenSA, BattaglinF, LenzHJ. Biomarker-driven and molecular targeted therapies for colorectal cancers. Semin. Oncol.45(3), 124–132 (2018).
   PubMed Web of Science ®Google Scholar
• Bagaria B , SoodS, SharmaR, LalwaniS. Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis). Cancer Biol. Med.10(3), 148–157 (2013).
   PubMedGoogle Scholar
• Chen CC , YangSH, LinJKet al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J. Surg. Res. 124(2), 169–174 (2005).
   PubMed Web of Science ®Google Scholar
• Park IJ , ChoiGS, JunSH. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Anticancer Res.29(10), 4303–4308 (2009).
   PubMed Web of Science ®Google Scholar
• Golubnitschaja O , PolivkaJJr, YeghiazaryanK, BerlinerL. Liquid biopsy and multiparametric analysis in management of liver malignancies: new concepts of the patient stratification and prognostic approach. EPMA J.9(3), 271–285 (2018).
   PubMed Web of Science ®Google Scholar
• Mihajlovic M , NinicA, SopicMet al. Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive and personalized medicine. EPMA J.10(3), 307–316 (2019).
   PubMed Web of Science ®Google Scholar
• Janssens JP , SchusterK, VossA. Preventive, predictive and personalized medicine for effective and affordable cancer care. EPMA J.9(2), 113–123 (2018).
   PubMed Web of Science ®Google Scholar
• Lu M , ZhanX. The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA J.9(1), 77–102 (2018).
   PubMed Web of Science ®Google Scholar
• Qian S , GolubnitschajaO, ZhanX. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J.10(4), 365–381 (2019).
   PubMed Web of Science ®Google Scholar